Home | About Brachytherapy | The Radiation Oncologist's Role

The Radiation Oncologist's Role

Brachytherapy provides a convenient way of delivering a higher dose of radiation to tumor cells than is possible with conventional external beam radiation therapy. Given that the radiation sources, either iodine-125 or palladium-103, are placed in or near the diseased tissue and have relatively low energies, the healthy surrounding tissue is spared an unnecessary dose of radiation.

IBt is committed to the development, manufacture and delivery of very high quality products. The goal of IBt sa's highly automated production processes is to produce sources of consistent activity. With the launch of both InterSource-103, a palladium seed, and InterSource-125, an iodine source, physicians will have the convenience of choosing either isotope from one company.

Published ten-year results by Dr. Haakon Ragde, using brachytherapy with or without external beam irradiation for the treatment of patients with clinically localized prostate carcinoma, indicate disease free survival (PSA < 0.5 ng/ml) rates up to 76%.

Seed Charcterisation for InterSource-103

The isodose curve for InterSource-103 is shown below:

Physics Manuscript
To request a copy of the InterSource-103 Physics Manuscript via e-mail click one of the links below:

• ibt@brachytherapy.be
• info@ibt4seeds.com

Seed Characterisation for InterSource-125

Seed Characterization of the InterSource-125 implant is complete and has been accepted for publication in Medical Physics.

Physics Manuscript
To request a copy of the InterSource-125 Physics Manuscript via e-mail, click one of the links below:

• ibt@brachytherapy.be
• info@ibt4seeds.com

Additional Information on brachytherapy

Med Phys:
http://sherouse.home.mindspring.com/MPFAQ/

Radiation Oncology:
www.radiation-oncology.com

AAPM's TG-69 Report:
http://www.aapm.org/pubs/reports/report069.pdf

Ragde, Elgamal, Snow, Brandt, Bartolucci, Nadir, Korb. Ten-Year Disease Free Survival after Transperineal Sonography-Guided Iodine-125 Brachytherapy with or without 45-Gray External Beam Irradiation in the Treatment of Patients with Clinically Localized, Low to High Gleason Grade Prostate Carcinoma. Cancer, 83: 989-1001 (1998).

Dattoli, M.D., M., et al, Pd-103 Brachytherapy and External Beam Irradiation for Clinically Localized, High-Risk Prostatic Carcinoma. International Journal Radiation Oncology Biology Physics, Vol. 35, No. 5, 875-879 (1996).

Blasko, M.D., J.C., et al, Should Brachytherapy be Considered a Therapeutic Option in Localized Prostate Cancer? Atlas of the Urologic Clinics of North America 23: 1033-1036 (1996).

Porter, M.D., A.T., et al, Brachytherapy for Prostate Cancer. CA a Cancer Journal for Clinicians, Vol.45, No. 3, 165-178 (1995).

Grimm, D.O., P.D., et al, Ultrasound-guided Transperineal Implantation of Iodine-125 and Palladium 103 for the Treatment of Early-stage Prostate Cancer. Atlas of the Urologic clinics of North America, Vol. 2, No. 2, 113-125 (1994).